Apogee Therapeutics Inc(APGE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.33 | Insider Own | 19.21% | Shs Outstand | 61.9M | Perf Week | - |
| Market Cap | 10.22B | Forward P/E | - | EPS next Y | -70.54% | Insider Trans | -1.5% | Shs Float | 61.3M | Perf Month | 0.27% |
| Enterprise Value | 9.36B | PEG | - | EPS next Q | -1.21 | Inst Own | 76.76% | Short Float | 6.86% | Perf Quarter | 49.45% |
| Income | -0.29B | P/S | - | EPS this Y | -16.23% | Inst Trans | -13.27% | Short Ratio | 1.52 | Perf Half Y | 97.18% |
| Sales | 0.00B | P/B | 8.52 | EPS next 5Y | -26.19% | ROA | -29.53% | Short Interest | 4.20M | Perf YTD | 78.95% |
| Book/sh | 15.86 | P/C | 10.52 | EPS past 3/5Y | -75.11% - | ROE | -32.46% | 52W High | -0.01% ($135.09) | Perf Year | 256.76% |
| Cash/sh | 12.84 | P/FCF | - | Sales past 3/5Y | - | ROIC | -22.67% | 52W Low | 281.66% ($35.39) | Perf 3Y | 446.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -6.36% | Gross Margin | - | Volatility(W/M) | 0.05% 0.11% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.33 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 26.44 | EPS Q/Q | -0.6% | Profit Margin | - | RSI (14) | 78.69 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 26.44 | Sales Q/Q | - | SMA20 | 0.22% ($134.77) | Beta | 0.35 | Target Price | $147.56 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/10 | SMA50 | 0.7% ($134.13) | Rel Volume | 0 | Prev Close | $135.07 |
| Employees | 261 | LT Debt/Eq | 0.09 | EPS/Sales Surpr. | -6.35% - | SMA200 | 46.86% ($91.97) | Avg Volume(3M) | 2.77M | Price | $135.07 |
| IPO | 2023/7/14 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🧬 This is a clinical-stage biotech company developing antibody therapeutics for inflammatory and immune diseases. It targets inflammatory and immune conditions such as atopic dermatitis and asthma, with next-generation antibody candidates designed to offer longer dosing intervals than existing treatments. As a bio-healthcare name, the stock price is heavily driven by clinical results and funding conditions.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
APGE has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -16.2% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +446.6%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 76.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #23 of 595 in the industry
Based on market cap of $10B.
APGE#23 Apogee Therapeutics Inc $10B PER - 
KYMR#23 Kymera Therapeutics Inc $10B PER - 
CAI#24 Caris Life Sciences Inc $10B PER 95.2 
MDGL#25 Madrigal Pharmaceuticals Inc $10B PER - 
PCVX#26 Vaxcyte Inc $10B PER - 
FAQ
What kind of company is APGE?
APGE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of APGE?
The market cap of APGE is approximately $10.2B, ranking 924 within its sector.
What is the 52-week high and low for APGE?
APGE has recorded a 52-week high of $135.09 and a low of $35.39.
